logo

For the Inventor, By the Inventor

Fuquay-Varina, NC, United States of America

Janet L Rideout

This inventor holds 63 USPTO granted patents, plus 1 CIPO patent, primarily in Purinergic Receptor Agonists (CPC class 514 ). Top assignees: Inspire Pharmaceuticals, Inc., Burroughs Wellcome Co., Glaxo Wellcome Inc.. Active years: 1981-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Janet L Rideout. Retrieved from https://idiyas.com/inventor/janet-l-rideout

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 63

% Patents Active = 92.1


Average Co-Inventor Count = 4.2

ph-index = 16

Forward Citations = 1,023(Granted Patents)

Forward Citations (Not Self Cited) = 942(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Chapel Hill, NC (US) (2004)
  • Raleigh, NC (US) (1981 - 2008)
  • Fuquay-Varina, NC (US) (2005 - 2012)

Company Filing History:

goldMedal31 out of 91 
 
Inspire Pharmaceuticals, Inc.
 patents
silverMedal23 out of 521 
 
Burroughs Wellcome Co.
 patents
bronzeMedal4 out of 281 
 
Glaxo Wellcome Inc.
 patents
4. 2 out of 1,327 
 
The University of North Carolina at Chapel Hill
 patents
5. 5 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1981-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Purinergic Receptor Agonists
Dry Eye Disease
Mucosal Hydration
Sinusitis Treatment
Dinucleoside Polyphosphates
Ciliary Dyskinesia
Pharmaceutical Formulation
Lacrimal System
Ciliary Beat Frequency
Viral Infections
Gastrointestinal Tract Disease
Bronchitis
63 patents (USPTO):Explore Patents
1. 8097600 - Method of increasing tear production with purinergic receptor agonists (2012-01-17),
2. 8008274 - P1-(2'-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis (2011-08-30),
3. 7759322 - Method of treating dry eye disease with purinergic receptor agonists (2010-07-20),
4. 7531525 - [object Object] (2009-05-12),
5. 7432252 - Method of promoting cervical and vaginal secretions (2008-10-07),
6. 7235535 - Method of enhancing drainage of lacrimal system with purinergic receptor agonists (2007-06-26),
7. 7223744 - Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof (2007-05-29),
8. 6977246 - Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency (2005-12-20),
9. 6921755 - Method of treating dry eye disease with purinergic receptor agonists (2005-07-26),
10. 6916794 - Method of enhancing drainage of lacrimal system with purinergic receptor agonists (2005-07-12),
11. 6887858 - Method of treating dry eye disease with purinergic receptor agonists (2005-05-03),
12. 6867199 - Dinucleoside polyphosphate compositions and their therapeutic use (2005-03-15),
13. 6696425 - Method of treating dry eye disease with purinergic receptor agonists (2004-02-24),
14. 6673779 - Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues (2004-01-06),
15. 6624150 - Method of treating gastrointestinal tract disease with purinergic receptor agonists (2003-09-23),

Title: Innovations and Contributions of Janet L. Rideout

Introduction

Janet L. Rideout, a prominent inventor based in Fuquay-Varina, NC, has made significant contributions to the field of pharmaceutical formulations and methods through her impressive portfolio of 63 patents. Her innovative work primarily focuses on improving health conditions related to tear production, retinal disorders, and related therapies.

Latest Patents

Among her latest inventions is a method to increase tear production using purinergic receptor agonists. This method entails administering substances such as uridine 5'-triphosphate (UTP) and adenosine 5'-triphosphate (ATP) to stimulate tear secretion in individuals. The approach includes various formats for administration, including topical and systemic routes. Furthermore, her work on P-(2'-deoxycytidine 5')-P-(uridine 5')-tetraphosphate aims to treat edematous retinal disorders and conditions like cystic fibrosis and sinusitis. These inventions showcase her commitment to advancing therapeutic options in eye care and respiratory health.

Career Highlights

Janet L. Rideout has collaborated with notable companies such as Inspire Pharmaceuticals, Inc. and Burroughs Wellcome Co., utilizing her expertise to drive innovation in the pharmaceutical industry. Her extensive background in research and development has played a critical role in the advancement of her patented methodologies and formulations.

Collaborations

Throughout her career, she has partnered with esteemed colleagues, including William Pendergast and Benjamin R. Yerxa, whose collective effort has contributed to the success of her inventions. Collaborations with other professionals in the field highlight the importance of teamwork in achieving innovative solutions and impactful discoveries.

Conclusion

Janet L. Rideout's work reflects her dedication to addressing critical health challenges through inventive solutions. With a strong foundation in research and collaboration, her contributions continue to influence the pharmaceutical landscape, paving the way for improved health outcomes and therapeutic advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…